The high prevalence of overweight and obesity in Mexican children

Blanca E del Río-Navarro1, Oscar Velázquez-Monroy, Claudia P Sánchez-Castillo

  • 1Hospital Infantil de Mexico, Federico Gómez, Mexico City, Mexico.

Obesity Research
|February 26, 2004
PubMed

Insights

Overweight and obesity affect Mexican children aged 10-17, with varying rates based on Centers for Disease Control and Prevention (CDC) and International Obesity Task Force (IOTF) criteria. Rates are higher in Northern Mexico, necessitating new public health strategies.

Area of Science:

  • Pediatric Endocrinology
  • Public Health Nutrition
  • Childhood Obesity Research

Background:

  • Childhood overweight and obesity represent a significant global health concern.
  • Understanding national and regional prevalence is crucial for targeted interventions.

Purpose of the Study:

  • To determine the prevalence of overweight and obesity in Mexican children aged 10-17 years.
  • To compare prevalence data using Centers for Disease Control and Prevention (CDC) and International Obesity Task Force (IOTF) criteria.

Main Methods:

  • Utilized data from the Mexican National Health Survey 2000, including 7862 boys and 8947 girls.
  • Measured height and weight to calculate Body Mass Index (BMI) percentiles.
  • Applied CDC and IOTF BMI criteria to categorize overweight and obesity.

Main Results:

  • Overweight prevalence (CDC) ranged from 10.8% to 19.1% and obesity from 6.8% to 14.7% across age and sex groups.
  • IOTF criteria yielded similar overweight rates but lower obesity rates.
  • Prevalence did not correlate with stunting, and higher rates were observed in Northern Mexico.

Conclusions:

  • Mexican children exhibit lower overweight/obesity prevalence compared to U.S. Mexican-American children.
  • Geographic disparities exist, with higher rates in Northern Mexico.
  • Urgent need for updated prevention and management policies for excess weight in this population.
Abstract

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Anorexia Nervosa01:28

Anorexia Nervosa

Anorexia nervosa is a complex and severe eating disorder characterized by an intense fear of weight gain, an unrelenting pursuit of thinness, and a distorted body image. It often leads to dangerously low body weight relative to an individual's age and height. This disorder is marked by significant physical and psychological consequences, making it one of the most life-threatening psychiatric illnesses.
Symptoms and Physical Effects
Individuals with anorexia nervosa commonly exhibit extreme...
Prevalence and Incidence01:08

Prevalence and Incidence

In statistical epidemiology and health sciences, two essential metrics—prevalence and incidence—are fundamental for understanding disease dynamics within a population. These measures enable public health officials, epidemiologists, and researchers to assess the burden of diseases, allocate resources effectively, and design impactful public health policies and interventions.
Prevalence indicates the proportion of individuals in a population who have a specific disease or health condition at a...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...